On July 17, 2026, InspireMD, Inc. received notice from Nasdaq that it is not in compliance with Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days ending July 16, 2026. The company has until January 13, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. The company is evaluating options to regain compliance, including a potential reverse stock split. InspireMD, Inc. operates in the medical device industry, developing and commercializing innovative technologies for the treatment of cardiovascular disease.
